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Long-term prognosis of patients with non-
ST-segment elevation myocardial infarction
according to coronary arteries
atherosclerosis extent on coronary
angiography: a historical cohort study
Karam Sadoon Alzuhairi1*, Peter Søgaard1,2, Jan Ravkilde1, Aziza Azimi3, Michael Mæng4, Lisette Okkels Jensen5
and Christian Torp-Pedersen3
Abstract
Background: Patients with non-ST-segment elevation myocardial infarction (NSTEMI) without obstructive coronary
artery disease (CAD) are often managed differently than those with obstructive CAD, therefore we aimed in this
study to examine the long-term prognosis of patients with NSTEMI according to the degree of CAD on coronary
angiography (CAG).
Methods: We examined 8.889 consecutive patients admitted for first time NSTEMI during 2000–2011, to whom CAG
was performed. Patients were classified by CAG into: 0-vessel disease (0VD), diffuse atherosclerosis (DA) (0% < stenosis
<50%), 1-vessel disease (1VD), 2VD, and 3VD with stenosis ≥50%. Follow-up period: 13 years (median 4.5).
Results: One-year mortality for NSTEMI patients with 0VD was 3.7%, DA 5.7%, 1VD 2.5%, 2VD 4.8%, and 3VD 11.
5%. Non-diabetic 0VD patients had higher risk of mortality than 1VD patients (HR:1.59; 95% CI:1.21–2.02; P < 0.001),
while those with diabetes mellitus (DM) had not significantly different risk. In addition 0VD group had higher risk
of heart failure (HF) (HR 1.61; 95% CI: 1.39–1.88; P < 0.001), and lower risk of recurrent MI (HR:0.55; 95% CI:0.39–0.
77; P < 0.001) compared with 1VD. For patients with DA; mortality and HF risks were higher than 1VD and not
different than 2VD, while recurrent MI risk was not different than 1VD and lower than 2VD.
Finally, the DA group had higher risk of mortality if they had DM, higher risk of recurrent MI, and not different risk
of HF and stroke compared with the 0VD group patients.
Conclusion: Patients with NSTEMI and non-obstructive CAD (both normal coronaries and diffuse atherosclerosis)
have a comparable prognosis to patients with one- or two-vessel disease. Patients with diffuse atherosclerosis
have worse prognosis than those with angiographically normal coronary arteries.
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Background
Non-ST-segment elevation myocardial infarction (NSTEMI)
with non-obstructive coronary arteries proven with coronary
angiography is an important subgroup of patients with
myocardial infarction (MI), because they are often man-
aged differently, being less likely to receive recommended
medical treatment after MI and more likely to discontinue
double platelet inhibitors, than patients with NSTEMI
with obstructive CAD [1, 2].
Studies investigating this subgroup reported a wide
range of prevalence (4–13%) according to the defini-
tions used, the type of MI, and the use of cardiac
troponin (MI or acute coronary syndrome (ACS)) [3–5].
Previous studies suggested that factors predicting non-
obstructive coronary arteries in MI patients are female,
younger age, and lack of smoking and diabetes mellitus
(DM) [2, 6, 7].
Previous studies showed that patients with NSTEMI
with non-obstructive CAD had better prognosis com-
pared with obstructive CAD [5, 6, 8–10]. Other studies
reported a substantial risk in non-obstructive group with
higher all-cause mortality [11] or similar risk of combined
death, MI, admission for ACS, and non-fatal stroke com-
pared with obstructive CAD group [2]. However, many of
these studies were limited by a small sample size [1, 12] or
a short duration of follow-up [6]. In addition, most of
these prognostic studies compared patients with obstruct-
ive versus non-obstructive CAD, and studies dividing both
these groups into subgroups according to coronary path-
ology are few [2, 10].
Therefore, the aim of this study was to assess the prog-
nosis in a large number of NSTEMI patients divided into
five groups according to their coronary artery atheroscler-
osis extent on the coronary angiography with a long-term
follow-up.
Methods
Study design
This was a historical prospective study based on data
collected from several Danish registries mentioned bellow.
All citizens in Denmark have a unique identification
number, which facilitates linkage between different
registries on person-level.
The registries
Since 1977 the Danish National Patient Register has
collected data including discharge diagnosis from all
admissions to Danish hospitals [13]. MI diagnosis is
with high sensitivity and specificity [14, 15].
The Western Denmark Heart Registry has collected
patient and procedure data since 1999 for all interven-
tions in the hospitals in western Denmark; and it is a
validated research source [16].
Study population
We identified all patients discharged with first time
NSTEMI or unspecific MI (ICD-10 codes: DI21.4 and
DI21.9, respectively) in the Patient Register during the
period January 1st, 2000 to August 31st, 2011, who
underwent coronary angiography within 30 days. Patients
discharged with unspecific MI diagnosis were included if
NSTEMI diagnosis was confirmed from the Western Heart
Registry, because this registry does not allow the use of
(unspecific MI) diagnosis. From this registry clinical
data and angiographic description of coronary arteries
stenosis were obtained Patients were divided accordingly
into five subgroups: zero-vessel disease (0VD) = angio-
graphically normal coronary arteries; diffuse atheroscler-
osis (DA) =moderate focal or diffuse atherosclerosis either
without stenosis ≥50%; one-vessel disease (1VD) with
stenosis ≥50%; two-vessel disease (2VD) with stenosis
≥50%; or three-vessel disease (3VD) with stenosis ≥50%.
Patients with left main stenosis ≥50% were included either
in the 3VD group, if the right coronary was hypoplastic or
with stenosis ≥50%, or in the 2VD group if the right
coronary was without significant stenosis. From the
Civil Registration System we obtained gender, age, and
mortality status.
Study outcomes
Recurrent MI was identified from the Patient Register
using ICD-10 code: DI21 (all types of MI). To avoid mis-
classification due to transfer between hospitals, we made
a program to merge related admissions into one, and
added 5 days after the discharge day, where no recurrent
MI can be considered.
Moreover, we did a sensitivity analysis where no re-
current MI was considered within the first 30 days.
Stroke event defined using ICD-10 code: DI61(intracereb-
ral haemorrhage), DI62 (other non-traumatic intracranial
haemorrhage), DI63 (cerebral infarction), or DI64 (stroke,
not specified). Patients with stroke diagnosis before
NSTEMI were not included in stroke outcome analysis.
To identify heart failure (HF) event, we used either ICD-
10 code: DI50.9 (heart failure, unspecified) or DI25.5
(ischemic cardiomyopathy).
Exclusion criteria
1- Missing data on coronary atherosclerosis description
(628 (6%) of study population).
2- Previous MI.
3- Known with HF.
4- Prior revascularization treatment.
Follow up and end points
During a median follow up period of 4.5 years (1.3–
13 years) the outcomes: mortality, recurrent MI, HF, and
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stroke were registered. Follow-up started on the day of
admission with first NSTEMI and ended on the 31st
December 2012, or the date of emigration or death.
Statistical analysis
Categorical variables are presented as numbers and
percentages and compared using Chi-square test, while
continuous variables presented as median with inter-
quartile range, and compared using analysis of variance.
Time to event curve was generated using Aalen-Nelson
cumulative incidence estimator taking into account death
as a competing risk.
Cox proportional hazard models were used to estimate
hazard ratio with 95% confidence interval. The model
was adjusted for: age, sex, DM, hypertension, current
smoker status, renal insufficiency (defined as estimated
glomerular filtration rate (eGFR) <60 ml/min/1.73m2
using MDRD equation), and overweight (defined as body
mass index ≥25). Left ventricular ejection fraction (EF)
was not included in the primary analysis because only 45%
of patients had available measurements; however, an add-
itional analysis was done separately for this subgroup.
Model assumptions for proportional hazard and linearity
were found valid. Effect modification was tested using
likelihood ratio test for clinically relevant variables: age,
sex, hypertension, DM, renal insufficiency, and smoking.
There was a significant and clinically important effect
modification of DM (P 0.003) on mortality outcome;
therefore we did the analysis with and without DM. No
significant effect modification was found for DM on the
other outcomes or for the other variables on all outcomes.
For more details in statistical analysis, please see online
appendix A. All statistical analyses were performed using
the SAS statistical software V.9.2 (SAS Institute Inc., Cary,
North Carolina, USA), and R version 3.02 (R Development
Core Team).
Results
Of 8889 first time NSTEMI patients who underwent
coronary angiography, 1290 (14.5%) had non-obstructive
coronary arteries. Of these 1290 patients, 988 (76.5%)
had 0VD, and 302 (23.5%) had DA with no stenosis
≥50%. The proportion of patients with non-obstructive
CAD increased throughout the study period reaching
18% in 2011.
Demographic data of the study population are showed
in Table 1. Patients with 0VD had a comparable risk
profile to those with 1VD except that the majority were
females (59.9% vs. 29.6% P < 0.001), and they were less
likely to be current smoker (32.4% vs. 42.7, P < 0.001) or
overweight (57.7 vs. 67.3, P < 0.001). However, patients
with 0VD were younger, more likely to be females, and
less likely to have hypertension and DM than patients
with DA. The DA group had similar characteristics to
the 2VD group, except it included more women (44.0%
vs. 23.3%, P < 0.001) and less overweight (55.6% vs. 66.7,
P < 0.001). Patients with all sub-groups of obstructive
CAD were significantly more frequently treated with
revascularization (either percutaneous coronary inter-
vention or coronary by-pass grafting (Table 1), they were
also more likely to receive double anti-platelet therapy
than patients with 0VD or DA (Table 1).
Long-term prognosis of NSTEMI patients according to
their coronary artery pathology
Mortality
Dividing NSTEMI patients according to coronary artery
disease extent revealed that one-year mortality for patients
with 0VD, DA, 1VD, 2VD, and 3VD were 36 (3.6%),
17(5.6%), 80(2.5%), 105(5.0%), and 251(11.5%), respectively
(Table 2). 1VD had the lowest and 3VD had the highest
unadjusted cumulative mortality rate (Fig. 1).
Patients with NSTEMI and without DM
After adjustment for covariates, mortality risk for the
0VD group was higher than the 1VD group (HR:1.59;
95% CI:1.21–2.02, P < 0.001) (Fig. 2, Additional file 1),
and not significantly different from the DA (HR:0.82;
95% CI:0.54–1.26, P = 0.37), 2VD (HR:1.19; 95% CI:0.91–
1.57, P = 0.21), and the 3VD groups (HR:0.83;95% CI:0.64–
1.08, P = 0.17). On the other hand, patients with DA had
higher risk of mortality compared with 1VD patients
(HR:1.93; 95% CI:1.31–2.83, P < 0.001), nominally higher,
but not statistically significant, compared with 2VD group
(HR:1.44; 95% CI:0.97–2.13, P = 0.06), and not different
than the 3VD group.
Patients with NSTEMI and DM
After multi-factorial adjustment, mortality risk for 0VD
patients was not significantly lower than the 1VD group
(Additional file 1), but significantly lower than the DA
(HR:0.16; 95% CI:0.05–0.51, P = 0.002), 2VD (HR:0.26;
95% CI:0.09–0.72, P = 0.01), and the 3VD groups
(HR:0.26; 95% CI:0.10–0.72, P = 0.009). For patients with
DA and diabetes, mortality risk was higher than 1VD
(HR: 2.5; 95% CI:1.28–4.90, P = 0.007), but not signifi-
cantly different compared with both 2VD and 3VD.
Recurrent MI
One-year risk of recurrent MI was lowest in patients with
non-obstructive CAD both the 0VD and the DA groups
(Table 2). The 3VD group had the highest incidence of re-
current MI throughout the study period (Fig. 3).
Patients with 0VD had the lowest risk of recurrent MI
in all groups after multi-factorial adjustment (Fig. 4), while
patients with DA had a risk of recurrent MI that
was higher than 0VD group (HR:1.7; 95% CI:1.05–
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2.89, P = 0.03), not significantly different from the 1VD
(HR:0.91; 95% CI:0.60–1.39, P = 0.66), and lower than
both the 2VD and 3VD groups. In patients with obstruct-
ive CAD, the risk of recurrent MI increased linearly with
the severity of the disease.
Heart failure
One-year HF risk after first NSTEMI was substantial in
patients with 0VD and DA (Table 2). Unadjusted cumu-
lative incidence of HF was lowest in 1VD and highest in
3VD group (Fig. 5). After multi-factorial adjustment, the
Table 2 One-year and five-year prognosis of patients with NSTEMI according to their coronary artery atherosclerosis extent
Outcomes 0VD
(N = 988)
DA
(N = 302)
1VD
(N = 3295)
2VD
(N = 2114)
3VD
(N = 2190)
1-year
Death 36 (3.6%) 17 (5.6%) 80 (2.4%) 105 (5.0%) 251 (11.5%)
Recurrent MI 35 (3.5%) 19 (6.3%) 273 (8.3%) 285 (13.5%) 369 (16.8%)
Heart Failure 101 (10.2%) 40 (13.2%) 263 (8.0%) 249 (11.8%) 433 (19.8%)
Stroke 17 (1.7%) 4 (1.3%) 42 (1.3%) 37 (1.8%) 69 (3.2%)
5-years
Death 120 (12.1%) 55 (18.2%) 327 (9.9%) 315 (14.9%) 609 (27.8%)
Recurrent MI 56 (5.7%) 29 (9.6%) 353 (10.7%) 360 (17.0%) 464 (21.2%)
Heart Failure 139 (14.1%) 45 (14.9%) 352 (10.7%) 367 (17.4%) 623 (28.4%)
Stroke 41 (4.1%) 16 (5.3%) 117 (3.6%) 94 (4.4%) 140 (6.4%)
The results presented in numbers (percent)
Abbreviations: 0VD zero-vessel disease, DA diffuse atherosclerosis, 1VD one-vessel disease, 2VD two-vessel disease, 3VD three-vessel disease
Table 1 Baseline characteristics of the study population
Variables 0VD
(N = 988)
DA
(N = 302)
1VD
(N = 3295)
2VD
(N = 2114)
3VD
(N2190)
P values
Age (years) 62 {53, 72} 66 {56, 74} 63 {54, 71} 67 {59, 75} 71 {63, 78} < 0.001
Female gender 585 (59.9) 131 (44.0) 966 (29.6) 489 (23.3) 587 (27.0) < 0.001
Hypertension 368 (39.2) 143 (49.7) 1290 (41.6) 875 (44.4) 1088 (53.6) < 0.001
Hyperlipidemia 427 (45.5) 144 (49.5) 1517 (48.9) 1060 (53.6) 1093 (53.9) < 0.001
Diabetes mellitus 106 (11.0) 51 (17.2) 413 (12.9) 342 (16.6) 488 (23.0) < 0.001
IHD in the family 347 (37.4) 113 (40.1) 1231 (40.5) 765 (39.3) 750 (37.9) 0.3072
Current smoker 293 (32.4) 100 (36.6) 1303 (42.7) 772 (39.4) 654 (33.0) < 0.001
Overweighta 463 (57.7) 143 (55.6) 1764 (67.3) 1097 (66.7) 1059 (64.4) < 0.001
Renal insufficiencyb 107 (13.8) 39 (15.4) 353 (13.8) 310 (19.0) 457 (28.0) < 0.001
EF < 50% 107 (22.1) 37 (25.2) 282 (19.5) 258 (28.7) 427 (42.3) < 0.001
Previous stroke 36 (3.6) 15 (5.0) 113 (3.4) 111 (5.3) 189 (8.6) < 0.001
Treatment
Any revascularisationc 26 (2.6) 15 (5.0) 2764 (83.9) 1816 (85.9) 1688 (77.1) < 0.001
PCI 21 (2.1) 11 (3.7) 2728 (82.8) 1588 (75.1) 769 (35.1) < 0.001
CABG 5 (0.5) 4 (1.3) 36 (1.1) 228 (10.8) 919 (42.0) < 0.001
Aspirin 883 (90.9) 288 (95.7) 3177 (96.6) 2039 (96.5) 2048 (93.8) <0.001
P2Y12 receptor inhibitor 668 (67.7) 235 (78.1) 3097 (94.2) 1920 (90.9) 1642 (75.2) <0.001
Beta blocker 758 (78.1) 263 (87.4) 2964 (90.1) 1892 (89.6) 1975 (90.5) <0.001
ACE-inhibitor 428 (44.1) 147 (48.8) 1641 (49.9) 1175 (55.6) 1363 (62.4) <0.001
Statin 808 (83.2) 277 (92.0) 3103 (94.3) 1968 (93.2) 1978 (90.6) <0.001
Parameters presented as numbers (percentages from non-missing data) or median (25th, 75th percentile)
Abbreviations: 0VD zero-vessel disease, DA diffuse atherosclerosis, 1VD one-vessel disease, 2VD two-vessel disease, 3VD three-vessel disease, IHD ischemic heart
disease, EF ejection fraction, PCI percutaneous coronary intervention, CABG coronary by-pass graft operation, P2Y12-inhibitor P2Y12 receptor inhibitor,
ACE angiotensin-converting-enzyme
aOverweight defined as body mass index ≥25
bRenal insufficiency defined as estimated glomerular filtration rate < 60 ml/min/1.73m2 using MDRD equation
cRevasculrisation defined as PCI within 30 days, and CABG within 60 days of non-ST-elevation myocardial infarction
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risk of HF was not significantly different between 0VD
and DA groups. Both groups had higher HF risk com-
pared with 1VD (Fig. 4), not statistically different com-
pared with 2VD, and lower risk compared with the 3VD
group (HR:0.80; 95% CI: 0.69–0.93, P = 0.004; and HR:
0.60; 95% CI: 0.44–0.83, P = 0.02), respectively.
Stroke
One-year stroke risk was highest in patients with 3VD and
comparable in the other 4 groups (Table 2). Incidence of
stroke was generally lower than other outcomes (Fig. 6).
Adjusted risk of stroke in patients with 0VD compared
with 1VD and 2VD were (HR:1.47; 95% CI: 0.98–2.20, P =
0.06) and (HR: 1.46; 95% CI: 0.95–2.23, P = 0.09), respect-
ively. Stroke risk was similar in the 0VD compared with
the DA and 3VD groups. Patients with DA had a similar
stroke risk compared with all other groups.
Additional analyses
Cardiovascular mortality
Considering only cardiovascular (CV) mortality and not
all-cause mortality: for patients without DM, the CV
mortality for 0VD group was higher compared to 1VD
(HR:1.52; 95% CI: 1.19–1.94, P = <0.001), not different
compared to DA and 2VD groups, and lower than 3VD
group (HR: 0.69; 95% CI:0.50–0.96, P = 0.02). While pa-
tients in the DA group had a CV mortality which was
higher than both 1VD and 2VD groups (HR: 1.82; 95% CI:
1.27–2.60, P = <0.001), (HR: 1.76; 95% CI: 0.91–1.82, P =
0.03), respectively, and not different compared to 3VD.
For patients with NSTEMI and DM, whose in the
0VD group had CV mortality which was not significantly
different compared to both 1VD, and 2VD groups, but
lower than CV mortality of both 3VD, and DA groups
(HR: 0.06; 95% CI:0.007–0.47, P = 0.007). While patients
in the DA group had higher CV mortality than 1VD
(HR:2.88; 95% CI:1.29–6.43, P = 0.009), and not different
compared to 2VD, and 3VD groups.
Fig. 1 Long-term mortality in patients with non-ST-segment
elevation myocardial infarction according to their coronary artery
atherosclerosis extent
Fig. 2 Adjusted mortality hazard ratio for NSTEMI patients according to their coronary artery pathology. 1VD group was used as a reference
group. The model was adjusted for age, sex, hypertension, renal insufficiency (eGFR < 60 ml/min/1.73m2), current smoker status, and
overweight (BMI ≥ 25)
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Patients with available EF measurement
This subgroup analysis consisted of 3986 patients. Multi-
factorial adjustment including EF revealed that stroke
hazard for 1VD group was significantly lower than all
other groups. No other differences were observed for the
other outcomes.
Sensitivity analysis considering recurrent MI only after 30 days
Recurrent MI risks from 30 to 365 days after NSTEMI
were as follows: 0VD 0.7% (0.2–1.2%), DA 3.3% (1.3–
5.5%), 1VD 2.4% (1.8–2.8%), 2VD 4.4% (3.6–5.3%) and
3VD 7.4% (6.3–8.4%). After adjustment for risk factors,
0VD continued to have the lowest risk of recurrent MI
among all groups. Patients with DA had a not signifi-
cantly different risk compared with the 1VD, 2VD, and
3VD groups.
Discussion
Our study recruited 8889 patients with a follow-up dur-
ation of up to 13 years (median 4.5 years). It showed
two important main findings: 1) NSTEMI patients with
non-obstructive CAD (both 0VD and DA without sig-
nificant stenosis) have a substantial risk of long-term
adverse outcomes comparable to 1VD and 2VD patients;
and 2) 0VD and DA groups are different in both risk
profile and outcome.
This study showed that patients with 0VD were younger,
mostly females, and had less co-morbidities than those
with DA. This was also observed in another study [2]. An
explanation of more females among both groups of non-
obstructive CAD group could be that one half of females
without significant stenosis have microvascular dysfunc-
tion [17].
The percentage of NSTEMI patients with non-obstructive
coronary arteries increased gradually during the study
to reach 18% in 2011, that might reflect the develop-
ment of more sensitive troponin and the use of lower
cut-off values in the definition of MI, and thus the
Fig. 3 Long-term recurrent myocardial infarction cumulative
incidence in patients with first NSTEMI divided by their coronary
artery atherosclerosis extent
Fig. 4 Adjusted hazard ratio of long-term recurrent myocardial infarction, heart failure, and stroke in patients with NSTEMI according to their
coronary artery disease. Hazard ratio was adjusted for age, sex, hypertension, diabetes mellitus, renal insufficiency (eGFR < 6060 ml/min/1.73m2),
current smoker status, and overweight (BMI≥ 25)
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detection of smaller injuries to the myocardium [18].
This means also that we are dealing with growing sub-
group of patients who need more attention in our
management.
Mechanism of NSTEMI with non-obstructive CAD
There are several reported mechanisms of myocardial
injury in these patients, like plaque disruption without
significant stenosis on the angiogram proven with intra
vascular ultrasound (IVUS) examination, [19] coronary
artery spasm, [12, 20] microvascular disease, [21] or
thrombophilias whether congenital or acquired [12]. Other
possible non ischemic mechanisms including myocarditis
which was observed in 7% of NSTEMI with non-
obstructive CAD using cardiac MRI [3].
In our study 2.6% of 0VD and 5.0% of DA were treated
with revascularization (either PCI or CABG). In the DA
group, the explanation could be proven plaque rupture
in non-obstructive lesion, and in the 0VD group, one of
the explanations could be complications to the coronary
angiography like perforation or dissection either with the
diagnostic catheter or with optical coherence or IVUS
wire. These complications might have led to revasculariza-
tion in a patient without CAD.
Long-term mortality after first NSTEMI
Our study illustrated that non-diabetic NSTEMI patients
with 0VD had higher mortality risk compared with 1VD
group. On the other hand, patients with DA had a 2-fold
higher mortality than those with 1VD and similar mor-
tality to those with 2VD.
Another study concluded that NSTEMI with normal
coronary arteries had the same mortality risk as both
atherosclerosis and low risk anatomy obstructive CAD
[10] while other studies showed no significant difference
in mortality in patients with and without obstructive
CAD after adjustment for risk factors for IHD [1, 7, 22].
A recent study reported higher risk of one-year mortality
in NSTEMI patients with non-obstructive compared with
obstructive CAD, mostly driven by non-cardiac death
[11]. These studies, however, did not divide obstructive
CAD into subgroups. A possible explanation for our find-
ings could be that as our results showed that patients with
NSTEMI with non-obstructive CAD were less likely to re-
ceive double anti-platelet therapy and other recommended
medical treatment after MI according to ESC guidelines,
[23]. This was also shown in another study, where these
patients were also more likely to discontinue double plate-
let inhibitors if these were started [1, 2]. Another explan-
ation might be that many of these patients, especially
those with 0VD, might have suffered a type II MI, and
comprises a heterogeneous group with different back-
ground pathology leading to myocardial injury without
CAD. Mortality risk of type II MI was reported to be com-
parable or higher than type I MI [24, 25].
Recurrent MI
NSTEMI patients with 0VD had the lowest risk of recur-
rent MI among our five groups, and those with DA had the
same risk as patients with 1VD. According to other studies,
patients with non-obstructive CAD have lower risk of MI
than obstructive CAD [2, 7]. However, these studies did not
divide obstructive CAD into subgroups. Our findings might
be explained by speculating that plaque burden might be
comparable in the DA and 1VD groups; and both have
higher plaque burden than the 0VD group. Previous studies
using IVUS reported that plaque rupture is often not de-
tected as significant stenosis by angiography, and is typically
associated with eccentric and large plaque with positive re-
modeling [19, 26, 27]. A recent meta-analysis ([28] showed
that shorter duration (<6 months) of double antiplatelet
therapy, was associated with higher incidence of MI,
less incidence of bleeding, and the same mortality and
stent thrombosis rates. However, this study was in patients
Fig. 6 Long-term stroke cumulative incidence in patients with first
NSTEMI divided by their coronary artery atherosclerosis extent
Fig. 5 Long-term heart failure cumulative incidence in patients with
first NSTEMI divided by their coronary artery atherosclerosis extent
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treated with PCI with second generation drug eluting
stent, nevertheless, about 40% of patients were acute cor-
onary syndrome patients. Although, our study population
is different, but our results also indicated that a non-
unreasonable anticipation is that some of the recurrent
MI incidence in DA group is because of either not been
given double anti-platelet therapy or shorter duration of
treatment compared with obstructive CAD group.
Heart failure
NSTEMI patients with both 0VD and DA had a higher
risk of HF than the 1VD, same risk as the 2VD, and
lower risk than the 3VD group in this study. Another
study showed that the risk of HF in ACS patients with
or without obstructive CAD was similar, [22] but that
study did not differentiate sub groups and included only
patients ≥75 years.
One explanation of our findings could be that some of
the patients were admitted with acute HF with symp-
toms, signs and troponin elevation that resembled MI. It
is well known that HF can cause myocardial injury resem-
bling MI [29]. However, we tried to restrict that possibility
by excluding patients known with HF. Another explan-
ation may be that especially patients with 0VD could have
a myocardial disease in early stage which developed after-
ward to a manifest HF.
Stroke
Patients with NSTEMI with non-obstructive CAD had a
similar risk of stroke compared with those with obstructive
CAD. This confirms the findings of other studies [1, 2].
Study strength and limitations
The strengths include the large number of unselected
patients with NSTEMI. Patients from both genders and
all age groups were included, which helps generalization
of our results.
However, our study has some limitations; patients with
MI type II might have been included if the primary dis-
charge diagnosis was NSTEMI, and it seems to be reason-
able to assume that this was more applicable to 0VD and
DA groups. These considerations, however, do not change
that, according to our data, these two groups remain at
high risk of adverse events. In angiography database the
definitions of 0VD and DA were subject for inter- and
intra-hospital different interpretations, thus some of the
patients with DA might have been coded as 0VD. However,
this misclassification would lead to minimize the differ-
ences between 0VD and DA groups, thus the real differ-
ences between these groups in outcome may be larger
than that reported in our article. A core-lab for coronary
angiography assessment was not used, thus inter-operator
variation might exist. Lastly, only patients who under-
went coronary angiography were included which make
generalization of the results limited. The cut-off values and
Troponin assays has been changed during the study years,
which might led to that the MI size detected in the later
years are smaller than that at the earlier years of the study.
Conclusion
Patients with NSTEMI with normal coronary arteries or
atherosclerosis without significant stenosis have substan-
tial risk of future cardiovascular events. Both patients
with 0VD without diabetes and patients with DA have
higher risk of mortality and heart failure compared with
patients with 1VD; and patients with DA have a similar
risk of recurrent MI compared with those with 1VD.
Moreover, patients with 0VD have favorable risk profile,
lower mortality (if patients were diabetic) and lower recur-
rent MI risk than patients with diffuse atherosclerosis.
These findings call for considering these two subgroups of
NSTEMI separately in future research and urge for further
investigations to explore the best management and follow-
up plans for each of these two subgroups.
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